See more than ever before

The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies
Detect relapse 200+ days earlier By detecting 1 part per million
See what others miss

Latest Updates

Jan 19, 2022

Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.

Dec 13, 2021

Foresight Diagnostics' PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas

Dec 13, 2021

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib